# DEC-C and Thioguanine for R/R AML

> **NCT06351306** · PHASE2 · WITHDRAWN · sponsor: **Columbia University**

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Thioguanine (Tabloid ®)
- **DRUG:** DecitabineCedazuridine (Inqovi ®)

## Key facts

- **NCT ID:** NCT06351306
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-04-01
- **Primary completion:** 2024-04-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Difficultly enrolling
- **Last updated:** 2025-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06351306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06351306, "DEC-C and Thioguanine for R/R AML". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06351306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*